The Nasdaq Stock Market will list its first cannabis shares on Tuesday, marking a key milestone for an industry that has been rejected by the Trump administration.
For all that’s worked in favor of marijuana stocks in recent years, there are plenty of risks. Some of these risks, such as profitability eluding most pot stocks, are readily apparent.
Legalized marijuana has a lot of investors having visions of lots of green. With legalization sweeping across the states, it seems to be a great time to invest in marijuana stocks. Unfortunately, it’s not.
The North American Marijuana Index, a stock index that tracks the top performing cannabis stocks in the U.S. and Canada, increased 18% in January.
Two of the top 10 most-traded shares in Sweden in January 2018 were Canada marijuana stocks, adding further proof that the marijuana market is growing more global with each passing day.
Anticipation is building for GW Pharmaceuticals (NASDAQ:GWPH) as the biotech prepares to hopefully launch its first product in the U.S. in 2018.
Canadian cannabis company Aphria Inc said on Thursday it was exploring strategic alternatives, including a sale, for its U.S. business, amid tightening enforcement of federal cannabis laws in the country.
Licensed marijuana producer Aphria Inc. announced an agreement Monday to buy medical cannabis firm Nuuvera Inc. in a cash-and-stock deal that it says values the company at $826 million.
A U.S. private equity firm investing exclusively in legal cannabis said on Thursday it had raised more than $100 million in its third round of fundraising, underscoring investor appetite for the burgeoning industry.
Canada’s No. 2 marijuana producer Aurora Cannabis Inc has agreed to buy smaller rival CanniMed Therapeutics Inc for C$1.1 billion ($852 million) as companies jostle to benefit from the country’s legalization of recreational marijuana use later this year.
Investors are betting Canada’s smaller financial firms could see a jump in revenues after they helped fund marijuana companies ahead of the country’s planned legalization of the drug this year.
Canadian marijuana producer Aurora Cannabis Inc (ACB.TO) is in talks with rivals CanniMed Therapeutics Inc (CMED.TO) and Newstrike Resources Ltd (HIP.V) to buy both businesses in a friendly deal that would create the nation’s top weed company, people familiar with the matter told Reuters on Friday.
Here’s Why Aurora Stock May Survive the Volatility. A simple case of acquisition has turned two marijuana companies—Aurora Cannabis Inc. (TSE: ACB), (OCTMKTS: ACBFF) and CanniMed Therapeutics Inc. (TSE: CMED), OCTMKTS: CMMDF)—into the biggest adversaries
A Canadian firm is launching an exchange-traded fund that gives investors exposure to the U.S. recreational marijuana market — a sector that’s been largely avoided by other ETFs because of legal uncertainties.
The North American Marijuana Index, a stock index that tracks the top performing cannabis stocks in the U.S. and Canada, increased 61% in December.
Aurora Cannabis Inc. (TSX:ACB) and Canopy Growth Corp. (TSX:WEED) are the two frontrunners in the rapidly emerging Canadian cannabis scene, but will these two powerhouses play leapfrog as legalization day comes and goes?
Canadian cannabis stocks fell on Thursday after the U.S. government said it would resume enforcement of federal laws banning marijuana in states that had legalized pot, disrupting a seven-day rally that boosted shares to record highs.
Marijuana companies are higher than ever as California rolls toward recreational legalization. The BI Canada Cannabis Competitive Peers index is having its best day ever as Californians prepare to light up, or eat up, marijuana products starting Jan. 1 at 12 a.m.
Medical marijuana maker CanniMed Therapeutics Inc (CMED.TO) should withdraw a shareholder rights plan adopted to fend off a hostile bid from larger rival Aurora Cannibis Inc ABC.TO, two Canadian regulators have ruled.
Merrill Lynch may have been one of the first mainstream investment firms to release a report on the burgeoning legal marijuana market back in 2015, but more have followed, including the Edward Jones marijuana report that recently entered the fray.
Medical marijuana maker Aphria Inc said on Thursday it would invest C$10 million ($7.80 million) in the proposed combination of two recreational marijuana companies to expand its presence in the sector.
You might be wondering what’s behind the big rally in cannabis stocks? While a generally bullish market has certainly helped, there are five other considerably more prominent reasons behind the rally in marijuana stocks in 2017.
Here’s why the marijuana market is so intriguing, how big the opportunity could be, and why these stocks are top stocks to own.
It was another big day of gains on Tuesday for the North American Marijuana Index, even as some investors anxiously wait for the Fed to announce an interest rate hike in the next 24 hours.
After gaining 15% in October, the Canadian market continued its rally as the Canadian Marijuana Index increased 52% in November, the largest single month increase since the index’s creation.
Medical marijuana company CanniMed Therapeutics Inc has asked Canadian regulators to intervene as it seeks to prevent a hostile takeover by bigger rival Aurora Cannabis Inc.
Aurora Cannabis has launched the first ever “hostile” takeover of another ACMPR Licensed Producer of Medical Marijuana. Executive Vice President Cam Battley lays out the case for why CanniMed shareholders should tender their shares to the Aurora bid.
A healthy day of trading for Canadian cannabis stocks led the North American Marijuana Index to gain several points over Monday’s 169.07 close.
Following market close on Dec. 4, 2017, Aphria Inc. (TSX:APH), an Ontario-based licensed producer of medical cannabis, made headlines when it announced that it had entered into an agreement to be the medical cannabis supplier for Shoppers Drug Mart, a Canadian pharmacy chain.
Canada’s Aurora Cannabis Inc (ACB.TO) said on Monday it increased its stake in Australia-based Cann Group Ltd (CAN.AX) to 22.9 percent from 19.9 percent, its latest move to expand in the cannabis industry.
The first U.S. exchange-traded fund, ETF, to focus on marijuana stocks is launching Dec. 26 — days before California legalizes recreational cannabis use on January 1.
The Marijuana Index, which covers leading cannabis investments on both sides of the Canada-U.S. border, rose 7% on Monday to close at 174.82.
Over the past year, investors have been anxiously following the progression of marijuana stocks such as Canopy Growth Corp, which offer the promise of significant growth from the new, emerging segment of the economy.
If it seems like there’s been a spurt of deals and potential deals going on in the cannabis industry lately, it’s because that’s exactly what’s happening.
Canada’s weed stocks, which have surrendered some of the potent gains that pushed them to record highs this month, face a bumpy ride in 2018 that could purge smaller players, as the country moves to allow recreational use of cannabis in July.
Say hello to the very first marijuana ETF for the U.S. As reported by CNBC, on Oct. 27, ETF Managers Group filed for a new ETF, the Alternative Agroscience ETF.
Not surprisingly, Canadian pot stocks have been the top performers of late, with Canopy Growth Corp. (NASDAQOTH:TWMJF), the now-largest marijuana stock in the world by market cap, leading the charge.
Vancouver-based Aurora Cannabis Inc. said Tuesday that it has made an all-share offer for CanniMed Therapeutics Inc., a fellow Canadian medical marijuana company.
A subsidiary of the New York Stock Exchange launches trading on Dec. 26 for its first-ever marijuana fund, a major step for an industry that’s struggled to access mainstream U.S. financial instruments, even as Canadian markets have kicked off marijuana investment.
At one point, MassRoots was flying high, raising millions of dollars from investors and attempting to become the first cannabis company listed on the Nasdaq.
Manitoba’s the latest province to unveil its plan for marijuana sales and distribution, releasing details Tuesday on how the new industry will operate.
The North American Marijuana Index, a stock index that tracks the top performing cannabis stocks in the U.S. and Canada, increased 4% in October.
Shares of Canopy Growth Corp. (TSX:WEED) have climbed a stunning 53.8% month over month as of close on November 1. With all of this in mind, has Canopy established itself as the premier cannabis stock for Canadians?
Founded in 2010, angel investment network The Arcview Group offers a window to gauge investor interest in legalized marijuana. Arcview’s network has invested $125 million in 157 cannabis-sector companies since 2013; membership in the network starts at $2,500. It plans to launch its own venture fund by the end of 2017.
The Auscann Group Holdings Ltd (ASX: AC8) share price had a day to remember on Tuesday. At one stage the medicinal cannabis company’s shares were up as much as 27% before finishing the day 23.5% higher at 52.5 cents.
Drinkable cannabis has been on the rise since the advent of states in America with recreational marijuana legalization and now that Canada is on the brink of implementing recreational legalization, a recently announced strategic relationship has the future of Canadian cannabis beverages looking bright.
Shares of Insys Therapeutics, a small-cap biotech with a focus on pain management, plunged as much as 30% on Wednesday after receiving a double whammy.
Knowledge Keiretsu caught up with professional investors Sturges Karban and Urban Smedeby, MJIC, Inc., a Los Angeles-based full-service cannabis company, to get their thoughts on navigating the opportunities and challenges of investing in the legal cannabis market.
The high-growth industry certainly offers terrific prospects that would be envied by many tech stocks. However, a big hurdle for some investors is investing in “sin stocks,” or what could be perceived as unethical industries and businesses.
There’s a massive Canadian marijuana news story that we’ve been following for over a year here at Money Morning. The news could lead to the Canadian cannabis industry growing by 400% in just four years, and you can profit by getting in right now…